AlzChem Group AG

  • WKN: A2YNT3
  • ISIN: DE000A2YNT30
  • Land: Deutschland

Nachricht vom 10.05.2019 | 06:30

AlzChem Group AG with planned sales and earnings development in the first quarter of 2019

DGAP-News: AlzChem Group AG / Key word(s): Quarterly / Interim Statement

10.05.2019 / 06:30
The issuer is solely responsible for the content of this announcement.

AlzChem Group AG with planned sales and earnings development in the first quarter of 2019
  • Positive market feedback on own distribution of Creamino
  • Full-year forecast with sales growth and stable earnings confirmed

Trostberg, May 10, 2019 - AlzChem Group AG, a vertically integrated specialty chemicals supplier with a leading market position in selected niche markets, looks back on a satisfactory start to the fiscal year 2019. Group sales in the first quarter of 2019 amounted to EUR 92.1 million (first quarter of 2018: EUR 94.5 million) and were thus in line with own expectations. In the Specialty Chemicals segment, the Dormex(R) business developed very successfully. In addition, AlzChem received consistently positive market feedback on the own distribution of Creamino launched at the beginning of the year. Overall, however, the Creamino destocking by the former sales partner led to the expected decline in sales in this segment, which could not be fully compensated by the increase in sales in the Basics & Intermediates segment.

Consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) also developed according to plan, reaching EUR 13.2 million after the first three months of 2019 (first quarter of 2018: EUR 15.1 million). As expected, among other things, the continued high procurement costs had an impact here. The EBITDA margin reached 14.4 % after 15.9 % in the prior-year quarter. Consolidated net income for the period amounted to EUR 5.6 million (first quarter of 2018: EUR 7.9 million).
In view of the planned sales and earnings development in the first three months of 2019, the Management Board confirms the full-year forecast, which includes, among other things, consolidated sales between EUR 389.9 million and EUR 398.9 million (2018: EUR 375.2 million) and adjusted EBITDA between EUR 46.5 million and EUR 51.9 million (2018: EUR 49.4 million).

The detailed quarterly statement for the first quarter of 2019 is available for download on the website under Investor Relations/Publications/Financial Reports.

About AlzChem
The AlzChem Group is a vertically integrated manufacturer of various chemical products based on the NCN chain. These are products with typical nitrogen-carbon-nitrogen bonding that are used in a wide variety of different industries. The company has a leading position in select niche markets. The strategic focus of growth and the main focus of its extensive research and development are on the business segment Specialty Chemicals. The company has around 1,560 employees at four sites in Germany and three other sites abroad.

10.05.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this


Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet

Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.

Aktuelle Research-Studie

amalphi AG

Original-Research: amalphi AG (von Sphene Capital GmbH): Buy

25. September 2020